Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uriel Heresco-Levy

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Expert Opinion on Emerging Drugs|November 3, 2005
Glutamatergic neurotransmission modulators as emerging new drugs for schizophreniaUriel Heresco-Levy
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 4, 2003
Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicalityUriel Heresco-Levy
Evidence-Based Mental Health|April 28, 2006
Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophreniaUriel Heresco-Levy
The International Journal of Neuropsychopharmacology|May 10, 2001
N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decadeUriel Heresco-Levy
Harefuah|November 23, 2006
[Expressed emotions (EE) towards schizophrenic patients among staff members of psychiatric wards and hostels: comparison and clinical implications]Gaby Sheflerz, Uriel Heresco-Levy
Molecular Psychiatry|November 9, 2023
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disordersUriel Heresco-Levy, Bernard Lerer
Schizophrenia Research|April 6, 2004
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisUriel Heresco-Levy, Daniel C Javitt
Harefuah|January 30, 2004
[Hypnosis: clinical applications]Noam Weizman, Uriel Heresco-Levy, Pesach Lichtenberg
The Israel Journal of Psychiatry and Related Sciences|March 7, 2007
Psychiatric manifestations in Turner Syndrome: a brief surveySara Catinari, Agnes Vass, Uriel Heresco-Levy
Psychiatry|February 18, 2004
Politics and psychopathology in an Arab-Israeli patientPesach Lichtenberg, Agnes Vass, Uriel Heresco-Levy
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Expert Opinion on Emerging Drugs|November 3, 2005
Glutamatergic neurotransmission modulators as emerging new drugs for schizophreniaUriel Heresco-Levy
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 4, 2003
Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicalityUriel Heresco-Levy
Evidence-Based Mental Health|April 28, 2006
Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophreniaUriel Heresco-Levy
The International Journal of Neuropsychopharmacology|May 10, 2001
N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decadeUriel Heresco-Levy
Harefuah|November 23, 2006
[Expressed emotions (EE) towards schizophrenic patients among staff members of psychiatric wards and hostels: comparison and clinical implications]Gaby Sheflerz, Uriel Heresco-Levy
Molecular Psychiatry|November 9, 2023
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disordersUriel Heresco-Levy, Bernard Lerer
Schizophrenia Research|April 6, 2004
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisUriel Heresco-Levy, Daniel C Javitt
Harefuah|January 30, 2004
[Hypnosis: clinical applications]Noam Weizman, Uriel Heresco-Levy, Pesach Lichtenberg
The Israel Journal of Psychiatry and Related Sciences|March 7, 2007
Psychiatric manifestations in Turner Syndrome: a brief surveySara Catinari, Agnes Vass, Uriel Heresco-Levy
Psychiatry|February 18, 2004
Politics and psychopathology in an Arab-Israeli patientPesach Lichtenberg, Agnes Vass, Uriel Heresco-Levy
Pageof 6